These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20097066)

  • 41. Discovery of novel isothiazole inhibitors of the TrkA kinase: structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists.
    Lippa B; Morris J; Corbett M; Kwan TA; Noe MC; Snow SL; Gant TG; Mangiaracina M; Coffey HA; Foster B; Knauth EA; Wessel MD
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3444-8. PubMed ID: 16632359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.
    Kawanishi N; Sugimoto T; Shibata J; Nakamura K; Masutani K; Ikuta M; Hirai H
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5122-6. PubMed ID: 16876403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Varani K; Borea PA
    J Med Chem; 2005 Jul; 48(15):5001-8. PubMed ID: 16033279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
    J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
    J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis.
    Gomez L; Hack MD; Wu J; Wiener JJ; Venkatesan H; Santillán A; Pippel DJ; Mani N; Morrow BJ; Motley ST; Shaw KJ; Wolin R; Grice CA; Jones TK
    Bioorg Med Chem Lett; 2007 May; 17(10):2723-7. PubMed ID: 17368897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 1,3-Dioxo-4-methyl-2,3-dihydro-1H-pyrrolo[3,4-c]quinolines as potent caspase-3 inhibitors.
    Kravchenko DV; Kysil VV; Ilyn AP; Tkachenko SE; Maliarchouk S; Okun IM; Ivachtchenko AV
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1841-5. PubMed ID: 15780618
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies.
    Gilbert AM; Nowak P; Brooijmans N; Bursavich MG; Dehnhardt C; Santos ED; Feldberg LR; Hollander I; Kim S; Lombardi S; Park K; Venkatesan AM; Mallon R
    Bioorg Med Chem Lett; 2010 Jan; 20(2):636-9. PubMed ID: 19969455
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and antiproliferative activity of tyrphostins containing quinoline moieties.
    Brunton VG; Lear MJ; McKeown P; Robins DJ; Workman P
    Anticancer Drug Des; 1996 Sep; 11(6):463-83. PubMed ID: 8836111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands.
    Ding K; Chen J; Ji M; Wu X; Varady J; Yang CY; Lu Y; Deschamps JR; Levant B; Wang S
    J Med Chem; 2005 May; 48(9):3171-81. PubMed ID: 15857123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and SAR/3D-QSAR studies on the COX-2 inhibitory activity of 1,5-diarylpyrazoles to validate the modified pharmacophore.
    Singh SK; Saibaba V; Rao KS; Reddy PG; Daga PR; Rajjak SA; Misra P; Rao YK
    Eur J Med Chem; 2005 Oct; 40(10):977-90. PubMed ID: 15961192
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
    Cappelli A; Pericot Mohr Gl Gl; Gallelli A; Rizzo M; Anzini M; Vomero S; Mennuni L; Ferrari F; Makovec F; Menziani MC; De Benedetti PG; Giorgi G
    J Med Chem; 2004 May; 47(10):2574-86. PubMed ID: 15115399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies.
    Da Settimo F; Primofiore G; La Motta C; Taliani S; Simorini F; Marini AM; Mugnaini L; Lavecchia A; Novellino E; Tuscano D; Martini C
    J Med Chem; 2005 Aug; 48(16):5162-74. PubMed ID: 16078836
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
    Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis.
    Tang J; Shewchuk LM; Sato H; Hasegawa M; Washio Y; Nishigaki N
    Bioorg Med Chem Lett; 2003 Sep; 13(18):2985-8. PubMed ID: 12941317
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a new cascade reaction for convergent synthesis of pyrazolo[1,5-a]quinoline derivatives under transition-metal-free conditions.
    Kato JY; Aoyama H; Yokomatsu T
    Org Biomol Chem; 2013 Feb; 11(7):1171-8. PubMed ID: 23306805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-activity relationships of imidazo[4,5-f]quinoline partial structures and analogs. Discovery of pyrazolo[3,4-f]quinoline derivatives as potent immunostimulants.
    Moyer MP; Weber FH; Gross JL
    J Med Chem; 1992 Nov; 35(24):4595-601. PubMed ID: 1469690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aristolochic acid derivatives from the rhizome of Arisolochia championii.
    Wang X; Shi GR; Liu YF; Li L; Chen RY; Yu DQ
    Fitoterapia; 2017 Apr; 118():63-68. PubMed ID: 28137630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.